NCT06759649 - A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

November 22, 2027

Study Completion Date

November 22, 2027

Conditions

NeoplasmCancer, Malignant Tumors

Interventions

DRUG

COM503

Intravenous Infusion

DRUG

Zimberelimab

Intravenous infusion

Trial Locations (5)

RECRUITING

NEXT Oncology Virginia, Fairfax

RECRUITING

START Midwest, Grand Rapids

RECRUITING

NEXT Oncology San Antonio, San Antonio

RECRUITING

START, San Antonio

RECRUITING

Beth Israel Deaconess Medical Center, Boston